The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study
Open accessAbstract
Objective: To estimate all cause mortality and cause specific mortality among patients taking proton pump inhibitors (PPIs). Design: Longitudinal observational cohort study. Setting: US Department of Veterans Affairs. Participants: New users of PPIs (n=157 625) or H2 blockers (n=56 842). Main outcome measures: All cause mortality and cause specific mortality associated with taking PPIs (values reported as number of attributable deaths per 1000 patients taking PPIs). Results: There were 45.20 excess deaths (95% confidence interval 28.20 to 61.40) per 1000 patients taking PPIs. Circulatory system diseases (number of attributable deaths per 1000 patients taking PPIs 17.47, 95% confidence interval 5.47 to 28.80), neoplasms (12.94, 1.24 to 24.28), infectious and parasitic diseases (4.20, 1.57 to 7.02), and genitourinary system diseases (6.25, 3.22 to 9.24) were associated with taking PPIs. There was a graded relation between cumulative duration of PPI exposure and the risk of all cause mortality and death due to circulatory system diseases, neoplasms, and genitourinary system diseases. Analyses of subcauses of death suggested that taking PPIs was associated with an excess mortality due to cardiovascular disease (15.48, 5.02 to 25.19) and chronic kidney disease (4.19, 1.56 to 6.58). Among patients without documented indication for acid suppression drugs (n=116 377), taking PPIs was associated with an excess mortality due to cardiovascular disease (22.91, 11.89 to 33.57), chronic kidney disease (4.74, 1.53 to 8.05), and upper gastrointestinal cancer (3.12, 0.91 to 5.44). Formal interaction analyses suggested that the risk of death due to these subcauses was not modified by a history of cardiovascular disease, chronic kidney disease, or upper gastrointestinal cancer. Taking PPIs was not associated with an excess burden of transportation related mortality and death due to peptic ulcer disease (as negative outcome controls). Conclusions: Taking PPIs is associated with a small excess of cause specific mortality including death due to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer. The burden was also observed in patients without an indication for PPI use. Heightened vigilance in the use of PPI may be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Identification of Causal Effects Using Instrumental Variables
Angrist, J. D., Imbens, G. W., & Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476902 · Cited by 4,230
Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling
Terza, J. V., Basu, A., & Rathouz, P. J. (2008) · Journal of Health Economics · doi:10.1016/j.jhealeco.2007.09.009 · Cited by 1,728
Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128
Austin, P. C. (2016) · Statistics in Medicine · doi:10.1002/sim.7084 · Cited by 542
The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution
Bowe, B., Xie, Y., Li, T., Yan, Y., Xian, H., & Al-Aly, Z. (2018) · The Lancet Planetary Health · doi:10.1016/s2542-5196(18)30140-2 · Cited by 371
Self-citationScally, B., Emberson, J. R., Spata, E., Reith, C., Davies, K., Halls, H., Holland, L., Wilson, K., Bhala, N., Hawkey, C., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30037-2 · Cited by 259
Cited by
High-dimensional characterization of post-acute sequelae of COVID-19
Al-Aly, Z., Xie, Y., & Bowe, B. (2021) · Nature · doi:10.1038/s41586-021-03553-9 · Cited by 1,518
Long COVID after breakthrough SARS-CoV-2 infection
Al-Aly, Z., Bowe, B., & Xie, Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01840-0 · Cited by 866
Self-citationRisks and burdens of incident diabetes in long COVID: a cohort study
Xie, Y., & Al-Aly, Z. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00044-4 · Cited by 564
Self-citationBurden of Cause-Specific Mortality Associated With PM 2.5 Air Pollution in the United States
Bowe, B., Xie, Y., Yan, Y., & Al-Aly, Z. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.15834 · Cited by 367
Self-citationBowe, B., Xie, Y., Xu, E., & Al-Aly, Z. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021060734 · Cited by 333
Self-citationRisks of mental health outcomes in people with covid-19: cohort study
Xie, Y., Xu, E., & Al-Aly, Z. (2022) · BMJ · doi:10.1136/bmj-2021-068993 · Cited by 323
Self-citationXie, Y., Bowe, B., & Al-Aly, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-26513-3 · Cited by 301
Self-citationSegna, D., Brusselaers, N., Glaus, D., Krupka, N., & Misselwitz, B. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211051463 · Cited by 56
Miao, J., & Herrmann, S. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad109 · Cited by 31
“Several large epidemiologic studies suggested that PPI use significantly increased the risk of incident chronic kidney disease (CKD), CKD progression, and kidney failure [32–35].”
Background
Metadata
- Authors
- Xie, Y., Bowe, B., Yan, Y., Xian, H., Li, T., & Al-Aly, Z.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2019-05-29
- Volume
- 365
- Pages
- l1580
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2946854190
- Cited by
- 228
- References
- 13
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.